FDA Set Low Standards for Nicotine Product Approval

Aug.12.2022
FDA Set Low Standards for Nicotine Product Approval
FDA sets low review standards for tobacco companies in determining the safety of nicotine products.

I'm sorry, but "smolaw11" is not a phrase or sentence that requires translation as it is not written in any language. It appears to be a username or a code. Please provide the correct text for me to translate to standard journalistic English.


In an article for Filter, Alex Norcia explained that the US Food and Drug Administration (FDA) has set a lower standard for review of nicotine products in its Center for Tobacco Products (CTP) to determine their suitability for preserving public health than for companies submitting tobacco product applications before they go to market.


Filter has cited documents obtained through the Freedom of Information Act, which describe procedures such as batching and bracketing that allow CTP to apply conclusions to product categories rather than individual evaluations. According to Alex Norcia, "Despite the extremely burdensome bureaucratic demands placed on applicants, the agency is pleased to have found ways to complete its paperwork.


It is evident that the FDA allows itself to take effective shortcuts, but it denies applicants," said Clive Bates, Director of The Counterfactual, in an interview with Filter Magazine.


The issue at hand is that the FDA's extensive process is a considerable waste of time and resources for applicants, but ultimately, it is something that the FDA evaluators cannot manage. Without this shortcut, the PMTA process would become a nightmare for human resources. Therefore, the FDA allows itself to achieve the efficiency it should provide to applicants by blending and packaging thousands of almost identical products.


Statement:


This article is compiled from third-party information and is intended for industry-related exchanges and learning.


This article does not represent the viewpoints of 2FIRSTS and we cannot confirm the authenticity or accuracy of its content. The translation of this article is only for industry-related research and exchange.


Due to limitations in translation proficiency, the translated article may not fully reflect the original text. Please refer to the original text for accuracy.


2FIRSTS maintains full alignment with the Chinese government on any statements and positions related to domestic, Hong Kong, Macau, Taiwan, and foreign affairs.


The copyright of compiled information belongs to the original media and author. If there is any infringement, please contact us for removal.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

Product | “Prefilled + Refill” Combo, Up to 30,000 Puffs Claimed: DOJO BLAST 30K PRO Launches in the UK and France
Product | “Prefilled + Refill” Combo, Up to 30,000 Puffs Claimed: DOJO BLAST 30K PRO Launches in the UK and France
DOJO has launched the upgraded BLAST 30K PRO on its official website. The device features a (2+8) ml ×2 “2 ml prefilled pod + 8 ml refill” configuration, delivering 20 ml of e-liquid per kit and claiming up to 30,000 puffs. It is also labeled as fully compatible with BLAST 10K Pods.
Jan.12 by 2FIRSTS.ai
BAT FY2025 Results Review Series by 2Firsts
BAT FY2025 Results Review Series by 2Firsts
Feb.12
Thai Health Authorities: Nicotine Pouches Classified as Tobacco; Sales Must Comply with 2017 Act
Thai Health Authorities: Nicotine Pouches Classified as Tobacco; Sales Must Comply with 2017 Act
Thailand’s Disease Control Department has warned that nicotine pouches (“Snus”) are classified as tobacco products and must comply with the Tobacco Products Control Act B.E. 2560 (2017). Officials said they have received complaints about sales and promotional activities, and stressed that these products must not be displayed or promoted at points of sale.
Feb.02 by 2FIRSTS.ai
German Environment Minister Backs Ban on Disposable E-Cigarettes, Citing Safety Risks
German Environment Minister Backs Ban on Disposable E-Cigarettes, Citing Safety Risks
Germany’s Environment Minister Carsten Schneider has expressed clear support for banning disposable e-cigarettes, citing safety hazards, environmental damage, and waste management risks. While the ban has not yet been finalized, Germany’s parliament has instructed the government to examine the proposal. Several European countries, including Belgium, France, and the UK, have already implemented similar bans.
Dec.30 by 2FIRSTS.ai
The UK government plans to expand the scope of its e-cigarette ban to include playgrounds, off-campus areas, and areas outside hospitals.
The UK government plans to expand the scope of its e-cigarette ban to include playgrounds, off-campus areas, and areas outside hospitals.
Government plans would ban vaping in cars carrying children and restrict smoking, vaping and heated tobacco in settings including playgrounds and outside schools across England, subject to a 12-week public consultation. The proposals also say indoor spaces where smoking is already banned would become vape- and heated-tobacco-free, and areas outside hospitals would be included.
Feb.13 by 2FIRSTS.ai
PMTA Manufacturing Panel Sees Small Firms Warn “Unknown Is Death” as FDA Defends Review Boundaries
PMTA Manufacturing Panel Sees Small Firms Warn “Unknown Is Death” as FDA Defends Review Boundaries
During FDA’s Feb 10 PMTA roundtable (manufacturing controls panel), small ENDS manufacturers warned that uncertainty in manufacturing expectations creates existential financial risk. FDA officials reiterated review flexibility is constrained by statutory and scientific boundaries. The panel debated testing standards, documentation requirements, open-system responsibility, supply chain changes, and software updates—highlighting unresolved PMTA challenges for small manufacturers.
Feb.11